{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T10:57:57Z","timestamp":1784285877556,"version":"3.55.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":691,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jtct.2021.03.018","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T11:48:05Z","timestamp":1616500085000},"page":"622.e1-622.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Continuous-Infusion Foscarnet Facilitates Administration in Hematopoietic Stem Cell Transplantation Patients"],"prefix":"10.1016","volume":"27","author":[{"given":"Walter","family":"Domingo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce J.","family":"Johnsrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice (Wes)","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2021.03.018_bib0001","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2165\/00003495-199141010-00009","article-title":"A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis","volume":"41","author":"Chrisp","year":"1991","journal-title":"Drugs"},{"key":"10.1016\/j.jtct.2021.03.018_bib0002","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.03.018_bib0003","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000167987","article-title":"Foscarnet nephrotoxicity: mechanism, incidence and prevention","volume":"9","author":"Deray","year":"1989","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jtct.2021.03.018_bib0004","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1128\/AAC.36.9.1821","article-title":"Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients","volume":"36","author":"Taburet","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jtct.2021.03.018_bib0005","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/00002030-199307000-00006","article-title":"A dose escalation study to determine the toxicity and maximally tolerated dose of foscarnet","volume":"7","author":"Seidel","year":"1993","journal-title":"AIDS"},{"key":"10.1016\/j.jtct.2021.03.018_bib0006","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1128\/AAC.33.5.736","article-title":"Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome","volume":"33","author":"Jacobson","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jtct.2021.03.018_bib0007","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/infdis\/166.3.473","article-title":"Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients","volume":"166","author":"Reusser","year":"1992","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jtct.2021.03.018_bib0008","series-title":"(foscarnet sodium) [prescribing information]","year":"2019"},{"key":"10.1016\/j.jtct.2021.03.018_bib0009","unstructured":"Kidney Disease Improving Global Outcomes. KDIGO clinical practice guidelines for acute kidney injury.Available at: https:\/\/kdigo.org\/wp-content\/uploads\/2016\/10\/KDIGO-2012-AKI-Guideline-English.pdf. Accessed January 10, 2021."},{"key":"10.1016\/j.jtct.2021.03.018_bib0010","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.bbmt.2020.05.007","article-title":"Treatment with foscarnet after allogeneic hematopoietic cell transplantation (allo-HCT) is associated with long-term loss of renal function","volume":"26","author":"Foster","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.03.018_bib0011","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2021.03.018_bib0012","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.03.018_bib0013","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.03.018_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2020.10.008","article-title":"Prophylactic foscarnet for human herpesvirus 6: effect on hematopoietic engraftment after reduced-intensity conditioning umbilical cord blood transplantation","volume":"27","author":"El Jurdi","year":"2021","journal-title":"Transplant Cell Ther"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721007958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721007958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:00:25Z","timestamp":1763002825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636721007958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S2666636721007958"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2021.03.018","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Continuous-Infusion Foscarnet Facilitates Administration in Hematopoietic Stem Cell Transplantation Patients","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2021.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}